89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewsWire • 09/08/21
89bio Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Treatment of NASHGlobeNewsWire • 08/02/21
89bio Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/12/21
89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/24/21
89bio Presents Additional Analysis of Phase 1b/2a NASH Study at the Annual ENDO 2021 ConferenceGlobeNewsWire • 03/20/21
89bio to Present at the 42nd Annual Raymond James Institutional Investors ConferenceGlobeNewsWire • 02/24/21
89bio To Participate in the Piper Sandler 32nd Annual Virtual Healthcare ConferenceGlobeNewsWire • 11/24/20
89bio Presents Updated Clinical Data from Positive Phase 1b/2a Study of BIO89-100 in NASH at AASLD's The Liver Meeting® 2020GlobeNewsWire • 11/13/20
89bio Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/10/20
89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASHGlobeNewsWire • 09/14/20
89bio to Announce Topline Results from Phase 1b/2a Study of BIO89-100 in NASHGlobeNewsWire • 09/13/20
89bio Initiates Phase 2 Trial of BIO89-100 in Patients with Severe HypertriglyceridemiaGlobeNewsWire • 09/03/20
89bio Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/13/20
89bio Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 07/13/20